Andrés Poveda
A5101925877- Ovarian cancer diagnosis and treatment
- Sarcoma Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Endometrial and Cervical Cancer Treatments
- BRCA gene mutations in cancer
- Gastrointestinal Tumor Research and Treatment
- Intraperitoneal and Appendiceal Malignancies
- Gastric Cancer Management and Outcomes
- Cancer Genomics and Diagnostics
- Vascular Tumors and Angiosarcomas
- Colorectal and Anal Carcinomas
- Cancer, Lipids, and Metabolism
- Renal cell carcinoma treatment
- Cancer-related molecular mechanisms research
- Gastrointestinal disorders and treatments
- Angiogenesis and VEGF in Cancer
- Cancer Mechanisms and Therapy
- Uterine Myomas and Treatments
- Metastasis and carcinoma case studies
- Genetic factors in colorectal cancer
- Lymphoma Diagnosis and Treatment
- Cardiac tumors and thrombi
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Cervical Cancer and HPV Research
Hospital Quirónsalud Barcelona
2019-2024
Spanish Ovarian Cancer Research Group
2012-2023
Fundación Instituto Valenciano de Oncología
2013-2022
Instituto do Câncer do Estado de São Paulo
2019
MedSIR (Spain)
2019
Délégation Paris 5
2017
Assistance Publique – Hôpitaux de Paris
2014-2017
Université Paris Cité
2010-2017
Birmingham Dental Hospital
2015-2017
Institut Català d'Oncologia
2009-2016
In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard. Bevacizumab active alone and in combination. AURELIA the first randomized phase III trial to our knowledge combining bevacizumab with OC.Eligible patients had measurable/assessable OC that progressed < 6 months after completing platinum-based therapy. Patients refractory disease, history of bowel obstruction, or > two prior anticancer regimens were ineligible. After investigators selected (pegylated liposomal...
The ICON7 trial previously reported improved progression-free survival in women with ovarian cancer the addition of bevacizumab to standard chemotherapy, greatest effect patients at high risk disease progression. We report final overall results trial.ICON7 was an international, phase 3, open-label, randomised undertaken 263 centres 11 countries across Europe, Canada, Australia and New Zealand. Eligible adult newly diagnosed that either high-risk early-stage (International Federation...
The objective of this study was to compare the efficacy and safety trabectedin plus pegylated liposomal doxorubicin (PLD) with that PLD alone in women recurrent ovarian cancer after failure first-line, platinum-based chemotherapy.Women > or = 18 years, stratified by performance status (0 1 v 2) platinum sensitivity, were randomly assigned receive an intravenous infusion 30 mg/m(2) followed a 3-hour 1.1 every 3 weeks 50 4 weeks. primary end point progression-free survival (PFS) independent...
To explore the prognostic value of mutations in c-KIT and PDGFR-alpha genes with respect to relapse-free survival (RFS) patients gastrointestinal stromal tumors (GIST). We have investigated relevance type position mutations, addition other clinicopathologic factors, a large series GIST.For this study, 162 were selected according following criteria: completely resected negative margins attended between 1994 2001; no metastasis at diagnosis; tumor larger than 2 cm, c-KIT-positive...
To assess the activity and toxicity of combination gemcitabine plus dacarbazine (DTIC) in patients with advanced soft tissue sarcoma (STS) a randomized, multicenter, phase II study using DTIC alone as control arm.Patients previously treated STS were randomly assigned to receive either fixed-dose rate (10 mg/m2/min) at 1800 mg/m2 followed by 500 every 2 weeks, or 1200 3 weeks. The primary end point was progression-free (PFR) months.From November 2005 September 2008, 113 included. PFR months...
Purpose A previous randomized clinical trial by the Italian Sarcoma Group (ISG) had shown a survival benefit of adjuvant chemotherapy (CT) in high-risk extremity soft tissue sarcoma (STS). However, dose-intensity last two cycles was suboptimal. We then undertook multicentric international phase III study to compare three and five same CT. Patients Methods were randomly assigned either receive preoperative CT with epirubicin 120 mg/m 2 ifosfamide 9 g/m granulocyte colony-stimulating factor...
Background: OVA-301 is a large randomized trial that showed superiority of trabectedin plus pegylated liposomal doxorubicin (PLD) over PLD alone in relapsed ovarian cancer. The optimal management patients with partially platinum-sensitive relapse [6–12 months platinum-free interval (PFI)] unclear.Patients and methods: Within OVA-301, we therefore now report on the outcomes for 214 cases this subgroup.Results: Trabectedin/PLD resulted 35% risk reduction disease progression (DP) or death...
LBA5002^ The full, final text of this abstract will be available at abstract.asco.org 12:01 AM (EDT) on Saturday, June 2, 2012, and in the Annual Meeting Proceedings online supplement to 20, issue Journal Clinical Oncology. Onsite Meeting, printed Saturday edition ASCO Daily News.
LBA5002^ Background: In three phase III trials in OC (2 front line, 1 PT-sensitive recurrent), BEV + CT → significantly improved progression-free survival (PFS) vs alone. AURELIA is the first randomized trial of PT-resistant OC. Methods: Eligible patients (pts) had (measurable by RECIST 1.0 or assessable) that progressed ≤6 mo after ≥4 cycles PT-based therapy. Pts with refractory OC, history bowel obstruction, >2 prior anticancer regimens were ineligible. After selection investigator...